Analysis of criteria for choosing drug treatment strategies in allergic rhinitis

Grzegorzewski D, Sobczak M, Tołkacz M, Pawliczak R. Front Pharmacol. 2024 Oct 1;15:1340554. doi: 10.3389/fphar.2024.1340554

Abstract

Background: Allergic rhinitis (AR) is the most common type of rhinitis, the treatment of which relies on relieving symptoms. Therefore, we aimed to assess the criteria that influence doctors' decision-making in the process of drug selection for the treatment of allergic rhinitis based on quantitative, qualitative, and cost analyses.

Methods: We conducted a survey study with the participation of 300 allergologists. A self-developed questionnaire was presented during a computer-assisted telephone interview (CATI) according tostandard procedures. The contingency table underwent statistical analysis using the chi-square test with Cramer's V. Results were considered statistically significant at p < 0.05.

Routes of drug administration preferred by patients
(A) overall (multiple choice) and (B) for oral drugs.

Results: Our analyses showed that doctors most often prescribe intranasal glucocorticoids and oral antihistamines to treat allergic rhinitis in patients of all ages. The most common factor that affects the decision-making related to AR treatment was the efficiency of the drug. We found a significant relationship between factors and the main workplace (X-squared = 122.81, df = 90, p-value = 0.0123, Cramer's V = 0.1787216), as well as voivodeship of the main workplace (X-squared = 440.75, df = 270, p-value = 2.378e-10, Cramer's V = 0.1954731).

In our study, respondents claimed that patients are willing to pay 31-50 PLN (∼€7- €11) monthly for the treatment of mild and moderate forms of AR, while they were willing to pay 51-100 PLN (∼€11-€22) for treatment of the severe AR form.

Conclusion: Our study confirms that the management of AR should be focused on the patient. One of the most important factors in choosing a drug is its effectiveness. Moreover, an important factor in the effective treatment of AR is the financial issue; as shown in our analysis, AR treatment costs can be a significant burden, especially for less wealthy citizens in Poland.

PDF